HIGHLIGHTS
- who: Julio Maria Fonseca Chebli and colleagues from the Program in Brazil Inflammatory Bowel Diseases Center, Federal University of Juiz de Fora, Juiz de Fora, Brazil have published the Article: Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohnu2019s Disease: Results from an Early Access Program in Brazil, in the Journal: (JOURNAL) of 30/08/2022
- what: The aim of this study was to assess the safety of ustekinumab (at induction and maintenance doses) in moderate-to-severely active CD in Brazil.
- how: The study was conducted in two phases a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.